Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Baxter
AstraZeneca
Moodys
Harvard Business School

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

ELLENCE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Ellence patents expire, and what generic alternatives are available?

Ellence is a drug marketed by Pfizer Inc and is included in one NDA.

The generic ingredient in ELLENCE is epirubicin hydrochloride. There are nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the epirubicin hydrochloride profile page.

Drug patent expirations by year for ELLENCE
Drug Prices for ELLENCE

See drug prices for ELLENCE

Recent Clinical Trials for ELLENCE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Lajos PusztaiPhase 2
AmgenPhase 3
Eisai Inc.Phase 2

See all ELLENCE clinical trials

Pharmacology for ELLENCE
Synonyms for ELLENCE
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside
(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-7-[[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione
10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione
15206-EP2269994A1
15206-EP2270008A1
15206-EP2270018A1
15206-EP2272827A1
15206-EP2275420A1
15206-EP2280012A2
15206-EP2281815A1
15206-EP2289892A1
15206-EP2292615A1
15206-EP2292617A1
15206-EP2295055A2
15206-EP2295416A2
15206-EP2295426A1
15206-EP2295427A1
15206-EP2298748A2
15206-EP2298764A1
15206-EP2298765A1
15206-EP2298768A1
15206-EP2298778A1
15206-EP2298780A1
15206-EP2301928A1
15206-EP2301933A1
15206-EP2305640A2
15206-EP2305642A2
15206-EP2305671A1
15206-EP2305689A1
15206-EP2308855A1
15206-EP2308861A1
15206-EP2311453A1
15206-EP2311808A1
15206-EP2311825A1
15206-EP2311827A1
15206-EP2311829A1
15206-EP2311840A1
15206-EP2311842A2
15206-EP2316832A1
15206-EP2316833A1
3Z8479ZZ5X
4-Epidoxorubicin
4'-epi-Doxorubicin
4'-epi-DX
4'-Epi-DXR
4'-Epiadriamycin
4'-epidoxorubicin
4'-Epidoxorubicin|||4'-Epiadriamycin|||(8S,10S)-10-(((2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-
56390-09-1 (hydrochloride)
56420-45-2
57918-25-9
A831042
AB00698552_15
AB00698552_16
AB00698552-11
AB00698552-13
AB00698552-14
AC1L26NP
AC1Q6JIV
Acid, 8
AK326115
AKOS027327569
AN-40147
AOJJSUZBOXZQNB-VTZDEGQISA-N
BDBM43839
BRD-K04548931-003-16-5
BRN 1445813
C11230
CCRIS 2261
CHEBI:47898
CHEMBL417
CS-2824
CTK8F9465
D07901
DB00445
Doxorubicin-13CD3 (discontinued)
DTXSID0022987
Epi-DX
Epiadriamycin
Epidoxorubicin
Epirubicin
Epirubicin (INN)
Epirubicin [INN:BAN]
EPIRUBICIN(Hydrochloride form)
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicin (TN)
FT-0630692
HSDB 6962
HY-13624
IMI 28
LS-187190
LS-93992
NCGC00263918-04
NSC 256942
NSC-256942
NSC256942
Pharmorubicin Pfs
Pidorubicin
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
SBI-0206890.P001
SCHEMBL8582
UNII-3Z8479ZZ5X
VA10821
WP 697
ZINC3938704

US Patents and Regulatory Information for ELLENCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc ELLENCE epirubicin hydrochloride INJECTABLE;INJECTION 050778-001 Sep 15, 1999 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer Inc ELLENCE epirubicin hydrochloride INJECTABLE;INJECTION 050778-002 Sep 15, 1999 AP RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Baxter
Merck
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.